Cytokinetics (CYTK) EVP exercises options and sells 15,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised options to acquire 15,000 shares of common stock at $23.26 per share and sold 15,000 shares in an open-market transaction at an average price of $63.26 per share.

After these transactions, Callos directly holds 58,555 shares of Cytokinetics common stock and 54,000 non-qualified stock options. The remaining options vest over four years from the grant date, with one quarter vesting after one year and the rest vesting monthly over the following 36 months, subject to continued employment.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($948,900)

Net Sell 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 15,000 shs ($949K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	15,000	$0.00	--
Exercise	Common Stock	15,000	$23.26	$349K
Sale	Common Stock	15,000	$63.26	$949K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 54,000 shares (Direct, null); Common Stock — 73,555 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 15,000 shares Sale price: $63.26 per share Options exercise price: $23.26 per share +3 more

6 metrics

Shares sold 15,000 shares Open-market sale of common stock on April 30, 2026

Sale price $63.26 per share Average price for 15,000 shares sold

Options exercise price $23.26 per share Exercise price for 15,000 options into common stock

Shares after transaction 58,555 shares Direct common stock holdings after April 30, 2026 transactions

Remaining options 54,000 options Non-qualified stock options remaining after 15,000 exercised

Option expiration March 31, 2031 Expiration date for exercised option grant

Key Terms

Non-Qualified Stock Option (Right to Buy), derivative exercise/conversion, open-market sale, stock options will vest over 4 years

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

stock options will vest over 4 years financial

"footnote: "Stock options will vest over 4 years from the date of the grant""

Form 4 Insider Transactions: What Each Field Means →

04/30/2026 - 04:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/30/2026		M		15,000	A	$23.26	73,555	D
Common Stock	04/30/2026		S		15,000	D	$63.26	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$23.26	04/30/2026		M			15,000	03/31/2022⁽¹⁾	03/31/2031	Common Stock	15,000	$0	54,000	D

Explanation of Responses:

1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cytokinetics (CYTK) EVP Andrew Callos report?

Andrew Callos reported an exercise-and-sell transaction. He exercised options for 15,000 Cytokinetics shares at $23.26 each, then sold 15,000 shares at an average price of $63.26, reflecting a routine monetization of part of his equity compensation.

How many Cytokinetics (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 15,000 shares of Cytokinetics common stock. The sale was executed in an open-market transaction at an average price of $63.26 per share, according to the Form 4 insider trading report filed for April 30, 2026.

At what price did Andrew Callos exercise his Cytokinetics (CYTK) stock options?

He exercised stock options to acquire 15,000 Cytokinetics shares at $23.26 per share. This option exercise converted part of his non-qualified stock options into common stock before the same number of shares was sold in the open market.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after these transactions?

Following the reported transactions, Andrew Callos directly holds 58,555 shares of Cytokinetics common stock. This figure reflects his remaining direct equity stake after exercising options and selling 15,000 shares in the open market on April 30, 2026.

How many Cytokinetics (CYTK) stock options does Andrew Callos still have?

After exercising 15,000 options, Andrew Callos retains 54,000 non-qualified stock options. These options continue to vest over a four-year schedule, with an initial one-year cliff and subsequent monthly vesting, subject to his continued employment with Cytokinetics.

What is the vesting schedule for Andrew Callos’s Cytokinetics (CYTK) stock options?

His stock options vest over four years from the grant date. One quarter of the underlying shares vests on the first anniversary, and the remaining three quarters vest monthly over the next 36 months, assuming he remains employed by Cytokinetics throughout the period.